Nuvalent Inc Cash Flow Conversion Efficiency
Nuvalent Inc cash flow conversion efficiency. Based on the latest financial reports, Nuvalent Inc (NUVL) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.40 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nuvalent Inc (2019–2025)
Cash flow conversion efficiency of Nuvalent Inc from 2019 to 2025. This chart illustrates how Nuvalent Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NUVL share price today for real-time trading data and today's change.
Nuvalent Inc Cash Flow Conversion Ratio Explained
Nuvalent Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nuvalent Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvalent Inc ranked by their cash flow conversion efficiency. Also see market value of Nuvalent Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ivanhoe Mines Ltd.
TO:IVN
|
-0.006x |
|
Orient Sec Co Ltd
SHG:600958
|
0.133x |
|
Banca Transilvania S.A.
RO:TLV
|
0.028x |
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
N/A |
|
China Spacesat Co Ltd
SHG:600118
|
0.022x |
|
Indra A
MC:IDR
|
0.004x |
|
YTO Express Group Co Ltd
SHG:600233
|
0.060x |
|
thyssenkrupp AG
XETRA:TKA
|
-0.120x |
Annual Cash Flow Conversion Efficiency for Nuvalent Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Nuvalent Inc from 2019 to 2025. Review NUVL financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.25 Billion | $-275.21 Million | -0.220x | -27.44% |
| 2024-12-31 | $1.07 Billion | $-185.06 Million | -0.173x | -21.51% |
| 2023-12-31 | $700.56 Million | $-99.74 Million | -0.142x | -1.45% |
| 2022-12-31 | $462.98 Million | $-64.97 Million | -0.140x | 0.00% |
| 2021-12-31 | $285.04 Million | $-40.00 Million | -0.140x | -129.40% |
| 2020-12-31 | $-31.32 Million | $-14.95 Million | 0.477x | -14.56% |
| 2019-12-31 | $-17.26 Million | $-9.64 Million | 0.559x | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more